Form 8-K - Current report:
SEC Accession No. 0000950170-25-091671
Filing Date
2025-06-30
Accepted
2025-06-30 16:47:12
Documents
10
Period of Report
2025-06-30
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K lxeo-20250630.htm   iXBRL 8-K 52225
  Complete submission text file 0000950170-25-091671.txt   161796

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lxeo-20250630.xsd EX-101.SCH 25989
12 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20250630_htm.xml XML 4931
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41855 | Film No.: 251092777
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)